SCHEMBL21873044

SCHEMBL21873044

Cc1nc(-c2cnc3n(c2=O)CCCN3C)ccc1C(=O)c1c[nH]c2ncccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 13/20 0.39
▸ CCNE1 P24864 10/20 0.39
▸ MAP2K1 Q02750 1/20 0.38
▸ CCNT1 O60563 3/20 0.36
▸ CCNA2 P20248 3/20 0.36
▸ CDK9 P50750 3/20 0.36
▸ CDK1 P06493 2/20 0.36
▸ CCNB1 P14635 2/20 0.36
▸ FLT3 P36888 2/20 0.36
▸ CDK7 P50613 1/20 0.36
▸ CCNH P51946 1/20 0.36
▸ MNAT1 P51948 1/20 0.36
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HSD11B1 P28845 2/20 0.35
▸ RET P07949 1/20 0.34
▸ CDC7 O00311 1/20 0.34
▸ DBF4 Q9UBU7 1/20 0.34
▸ KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21873129 0.82 GPR84 (0.42) CDK2CCNE1CCNT1CCNA2CDK9
SCHEMBL21977192 0.80 CSF1R (0.43) CDK2CCNE1MAP2K1CCNT1CCNA2
SCHEMBL21872995 0.74 CSF1R (0.48) CDK2CCNE1MAP2K1CCNT1CCNA2
SCHEMBL21873132 0.73 CYP3A4 (0.31) CYP2C19
SCHEMBL21873050 0.73 GPR84 (0.41) CDK2CCNE1CCNT1CCNA2CDK9
SCHEMBL21873018 0.72 CYP2C19 (0.39) FLT3CYP2C9CYP2C19KDR
SCHEMBL21872991 0.71 MAP2K1 (0.43) CDK2CCNE1MAP2K1CCNT1CCNA2
SCHEMBL21872989 0.71 CYP3A4 (0.37) FLT3CYP2C9CYP2C19KDR
SCHEMBL21873045 0.71 CYP3A4 (0.41) FLT3CYP2D6CYP2C9CYP2C19KDR
SCHEMBL21873036 0.70 CYP1A2 (0.39) FLT3CYP2C9CYP2C19KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CSF1R, CSF3R, FSHR CDK2 2260/4885CCNE1 1232/4885MAP2K1 2519/4885
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof CSF1R, CSF3R, FSHR CDK2 2260/4885CCNE1 1232/4885MAP2K1 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback